Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients

Figure 4 Potential prognostic markers of the response to nivolumab therapy in hepatocellular carcinoma patients. A and B: At the phylum level, a skewed Firmicutes/Bacteroidetes ratio (< 0.5 or > 1.5) was more frequent in the non-responders than the responders (66.7% vs 10.0%, P = 0.018); C: At the genus level, the ratio of Prevotella species to Bacteroides species (P/B ratio) was a prognostic marker of the response to nivolumab in hepatocellular carcinoma patients. The responders showed a significantly higher mean P/B ratio than the non-responders (22.99 vs 2.312, P = 0.024). NS: Statistically non-specific.